1. Medtech Insight
  2. >>Archive

Start-Up News January 2008

Noteworty news from medtech start-ups. In this issue: NOTES companies promise the least invasive surgery, with brief profiles of Apollo Endosurgery, Minos Medical and Cardiorobotics. (Adapted from "NOTES Companies Sing an Upbeat Tune," START-UP, December 2007.)

NOTES (Natural Orifice Translumenal Endoscopic Surgery) is an acronym for the latest wave in minimally invasive surgery, in which procedures will be done through a natural orifice like the mouth or the anus, leaving no scar on the outside of the body and offering a reduction in pain and healing times compared with open and even laparoscopic surgeries. The new field covers both procedures that are performed endoscopically within the lumens of organs—the bowel, the stomach, or the vagina, for example--that can be reached with scopes in a non-invasive manner (endolumenal approach), and even more revolutionary surgeries in which clinicians will breach the walls of those organs to access the peritoneal cavity or some other space in the body (translumenal approach).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight